A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy

NCT00673920 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

314

Enrollment

INDUSTRY

Sponsor class

Stopped Based on analysis of results and consideration of available treatments, the overall benefit to risk profile of ocrelizumab was not favorable in RA.

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Methotrexate
DRUG: Ocrelizumab
DRUG: Placebo

Sponsor

Genentech, Inc.

Collaborators

[object Object]